Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Jun;80(7):964–970. doi: 10.1038/sj.bjc.6690450

Enhanced delivery of carboplatin into brain tumours with intravenous CereportTM (RMP-7): dramatic differences and insight gained from dosing parameters

D F Emerich 1, P Snodgrass 1, R Dean 1, M Agostino 1, B Hasler 1, M Pink 1, H Xiong 1, B S Kim 1, R T Bartus 1,2
PMCID: PMC2363031  PMID: 10362103

Abstract

CereportTM (RMP-7) is a selective bradykinin B2 receptor agonist which increases the permeability of the ‘blood–brain tumour barrier’ (BBTB) to increase delivery of chemotherapeutic agents to brain tumours. A series of experiments was performed in an RG2 rodent model of glioma to evaluate and refine intravenous (i.v.) parameters to optimize Cereport's clinical utility. The first experiment demonstrated that while carboplatin levels were increased by twofold when given as a bolus during the Cereport infusion, no increase in carboplatin levels were seen when Cereport and carboplatin were simultaneously co-infused for 15 min. A subsequent experiment established that a major factor responsible for the lack of an effect with the co-infusion paradigm was tachyphylaxis to Cereport during the 15 min infusion, for a progressively diminished response to Cereport occurred over that time frame, as plasma levels of carboplatin were rising. A final experiment adjusted the timing of the Cereport and carboplatin infusions so that higher plasma carboplatin levels were achieved prior to initiating the Cereport infusion. Significant uptake effects were achieved when the carboplatin infusion preceded the Cereport infusion by 10 min (i.e. 5 min overlap in the delivery of the two agents). Collectively, these data provide the first systematic evaluation of dosing parameters involving receptor-mediated changes in BBTB permeability and provide new information regarding the pharmacodynamics and potential clinical use of Cereport. © 1999 Cancer Research Campaign

Keywords: glioma, blood–brain barrier, chemotherapy, drug delivery, tumour barrier

Full Text

The Full Text of this article is available as a PDF (142.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bartus R. T., Elliott P. J., Dean R. L., Hayward N. J., Nagle T. L., Huff M. R., Snodgrass P. A., Blunt D. G. Controlled modulation of BBB permeability using the bradykinin agonist, RMP-7. Exp Neurol. 1996 Nov;142(1):14–28. doi: 10.1006/exnr.1996.0175. [DOI] [PubMed] [Google Scholar]
  2. Bartus R. T., Elliott P., Hayward N., Dean R., McEwen E. L., Fisher S. K. Permeability of the blood brain barrier by the bradykinin agonist, RMP-7: evidence for a sensitive, auto-regulated, receptor-mediated system. Immunopharmacology. 1996 Jun;33(1-3):270–278. doi: 10.1016/0162-3109(96)00070-7. [DOI] [PubMed] [Google Scholar]
  3. Black K. L., Cloughesy T., Huang S. C., Gobin Y. P., Zhou Y., Grous J., Nelson G., Farahani K., Hoh C. K., Phelps M. Intracarotid infusion of RMP-7, a bradykinin analog, and transport of gallium-68 ethylenediamine tetraacetic acid into human gliomas. J Neurosurg. 1997 Apr;86(4):603–609. doi: 10.3171/jns.1997.86.4.0603. [DOI] [PubMed] [Google Scholar]
  4. Doctrow S. R., Abelleira S. M., Curry L. A., Heller-Harrison R., Kozarich J. W., Malfroy B., McCarroll L. A., Morgan K. G., Morrow A. R., Musso G. F. The bradykinin analog RMP-7 increases intracellular free calcium levels in rat brain microvascular endothelial cells. J Pharmacol Exp Ther. 1994 Oct;271(1):229–237. [PubMed] [Google Scholar]
  5. Elliott P. J., Hayward N. J., Dean R. L., Bartus R. T. Dissociation of blood-brain barrier permeability and the hypotensive effects of the bradykinin B2 agonist, RMP-7. Immunopharmacology. 1996 Jun;33(1-3):205–208. doi: 10.1016/0162-3109(96)00041-0. [DOI] [PubMed] [Google Scholar]
  6. Elliott P. J., Hayward N. J., Dean R. L., Blunt D. G., Bartus R. T. Intravenous RMP-7 selectively increases uptake of carboplatin into rat brain tumors. Cancer Res. 1996 Sep 1;56(17):3998–4005. [PubMed] [Google Scholar]
  7. Elliott P. J., Hayward N. J., Huff M. R., Nagle T. L., Black K. L., Bartus R. T. Unlocking the blood-brain barrier: a role for RMP-7 in brain tumor therapy. Exp Neurol. 1996 Oct;141(2):214–224. doi: 10.1006/exnr.1996.0156. [DOI] [PubMed] [Google Scholar]
  8. Inamura T., Nomura T., Bartus R. T., Black K. L. Intracarotid infusion of RMP-7, a bradykinin analog: a method for selective drug delivery to brain tumors. J Neurosurg. 1994 Nov;81(5):752–758. doi: 10.3171/jns.1994.81.5.0752. [DOI] [PubMed] [Google Scholar]
  9. Matsukado K., Inamura T., Nakano S., Fukui M., Bartus R. T., Black K. L. Enhanced tumor uptake of carboplatin and survival in glioma-bearing rats by intracarotid infusion of bradykinin analog, RMP-7. Neurosurgery. 1996 Jul;39(1):125–134. doi: 10.1097/00006123-199607000-00025. [DOI] [PubMed] [Google Scholar]
  10. Matsukado K., Sugita M., Black K. L. Intracarotid low dose bradykinin infusion selectively increases tumor permeability through activation of bradykinin B2 receptors in malignant gliomas. Brain Res. 1998 May 4;792(1):10–15. doi: 10.1016/s0006-8993(97)01502-3. [DOI] [PubMed] [Google Scholar]
  11. Munoz C. M., Leeb-Lundberg L. M. Receptor-mediated internalization of bradykinin. DDT1 MF-2 smooth muscle cells process internalized bradykinin via multiple degradative pathways. J Biol Chem. 1992 Jan 5;267(1):303–309. [PubMed] [Google Scholar]
  12. Neuwelt E. A., Barnett P. A., McCormick C. I., Frenkel E. P., Minna J. D. Osmotic blood-brain barrier modification: monoclonal antibody, albumin, and methotrexate delivery to cerebrospinal fluid and brain. Neurosurgery. 1985 Sep;17(3):419–423. doi: 10.1227/00006123-198509000-00004. [DOI] [PubMed] [Google Scholar]
  13. Neuwelt E. A., Hill S. A., Frenkel E. P. Osmotic blood-brain barrier modification and combination chemotherapy: concurrent tumor regression in areas of barrier opening and progression in brain regions distant to barrier opening. Neurosurgery. 1984 Sep;15(3):362–366. doi: 10.1227/00006123-198409000-00011. [DOI] [PubMed] [Google Scholar]
  14. Neuwelt E. A., Rapoport S. I. Modification of the blood-brain barrier in the chemotherapy of malignant brain tumors. Fed Proc. 1984 Feb;43(2):214–219. [PubMed] [Google Scholar]
  15. Nomura T., Inamura T., Black K. L. Intracarotid infusion of bradykinin selectively increases blood-tumor permeability in 9L and C6 brain tumors. Brain Res. 1994 Oct 3;659(1-2):62–66. doi: 10.1016/0006-8993(94)90863-x. [DOI] [PubMed] [Google Scholar]
  16. Ohno K., Pettigrew K. D., Rapoport S. I. Lower limits of cerebrovascular permeability to nonelectrolytes in the conscious rat. Am J Physiol. 1978 Sep;235(3):H299–H307. doi: 10.1152/ajpheart.1978.235.3.H299. [DOI] [PubMed] [Google Scholar]
  17. Riley M. G., Kim N. N., Watson V. E., Gobin Y. P., LeBel C. P., Black K. L., Bartus R. T. Intra-arterial administration of carboplatin and the blood brain barrier permeabilizing agent, RMP-7: a toxicologic evaluation in swine. J Neurooncol. 1998 Jan;36(2):167–178. doi: 10.1023/a:1005751922174. [DOI] [PubMed] [Google Scholar]
  18. Sanovich E., Bartus R. T., Friden P. M., Dean R. L., Le H. Q., Brightman M. W. Pathway across blood-brain barrier opened by the bradykinin agonist, RMP-7. Brain Res. 1995 Dec 24;705(1-2):125–135. doi: 10.1016/0006-8993(95)01143-9. [DOI] [PubMed] [Google Scholar]
  19. Straub J. A., Akiyama A., Parmar P. In vitro plasma metabolism of RMP-7. Pharm Res. 1994 Nov;11(11):1673–1676. doi: 10.1023/a:1018986510570. [DOI] [PubMed] [Google Scholar]
  20. Ziylan Y. Z., LeFauconnier J. M., Bernard G., Bourre J. M. Effect of dexamethasone on transport of alpha-aminoisobutyric acid and sucrose across the blood-brain barrier. J Neurochem. 1988 Nov;51(5):1338–1342. doi: 10.1111/j.1471-4159.1988.tb01094.x. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES